All In Biotech

Drug Trial Radar · NCT06300723

Clinical Study of BRL-101 in Severe SCD

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

3

Planned (sponsor's estimate)

Start

Jul 29, 2024

Primary completion

Mar 20, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
Bioray LaboratoriesIndustry
Sponsor type
Industry
Collaborators
First Affiliated Hospital of Guangxi Medical University
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101).

Conditions

  • Sickle Cell Disease

Interventions

  • BRL-101Drug

    CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of stem cell engrafted subjectsTime frame: Within 42 Days After BRL-101 Infusion
  2. Time to neutrophil engraftmentTime frame: Within 42 Days After BRL-101 Infusion
  3. Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusionTime frame: Up to 12 Months After BRL-101 Infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.